Navigation Links
MedImmune Submits Biologics License Application to FDA for Motavizumab
Date:2/4/2008

GAITHERSBURG, Md., Feb. 4 /PRNewswire/ -- MedImmune announced today it submitted to the U.S. Food & Drug Administration (FDA) on January 30 a Biologics License Application (BLA) for motavizumab, an investigational monoclonal antibody (MAb) derived from recombinant DNA technology. The motavizumab BLA is supported by clinical trial data from more than 6,000 patients in which safety and efficacy in prevention of serious disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients were evaluated.

"We are pleased to submit this BLA for motavizumab, which we believe represents another tool in the fight against RSV. This marks a significant milestone for this molecule and further reinforces MedImmune's commitment to developing anti-RSV biologics for the underserved pediatric patient population," said Linda J. Peters, senior vice president, regulatory affairs.

Motavizumab was studied in an active-controlled Phase 3 trial against the standard of care in pediatric patients at high risk of serious RSV disease. Primary and secondary endpoints of the study included incidence of RSV hospitalizations and RSV-specific medically attended outpatient lower respiratory tract infections. Rates of adverse events, serious adverse events and study drug discontinuations were balanced between treatment groups. The most frequently observed reactions versus the active comparator were cutaneous reactions (overall).

"Beyond the findings of the various investigational trials for motavizumab, we believe this molecule will help reinforce the positive role that MAbs play in RSV prevention within the current clinical body of evidence. It also reinforces our position as a leader in RSV prevention," said Genevieve Losonsky, M.D., vice president, clinical development, infectious disease.

RSV is a leading cause of viral respiratory infection among infants. Each year, up to an estimated 125,000 infants in the United States are hospitalized with sev
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
2. MedImmune Announces Seven Key Promotions and New Hires
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
6. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
7. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Cephalon Submits Supplemental New Drug Application for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...menopause to postmenopause , , MONTVALE, N....y and intensity of vasomotor symptoms is a challen...nt and The Journal of Family Practice have rece...toms: Managing the transition from perimenopause t...or, MD, CM and Lee P. Shulman, MD, discuss the ben...
(Date:12/2/2008)...Applied BioSciences has turned to MBI Internationa...cial viability of an important bio-based product l... gap between research and commercialization throug...es. MBI’s unique “Collaborative De-Ris...ological uncertainties, which impede new technolog...
(Date:12/2/2008)...wire/ -- GeneGo, Inc., the leading systems biology...ecome a certified GeneGo Center of Excellence. Bur... to GeneGo,s MetaCore data analysis suite, trainin...a world-class biomedical research facility running...ny departments, including research in cancer, stem...
(Date:12/2/2008)...wire/ -- Intradigm Corporation, a leading,develop...herapeutics, today,announced the issuance of Unit... Compositions for Controlling Efficacy of RNA Sile... seminal research of Philip Zamore, Ph.D., the,Gr... Professor of Biochemistry,& Molecular Pharma...
Breaking Biology Technology: DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product 2The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology 2Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 2Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 3
... Wis. - This summer, venture investors deployed m...s Wisconsin, a total that may bode well for improv...ile it is difficult to draw firm conclusions from ...ld indicate that technologically innovative compan...ase of capital in 2006. , ,"With the growth of the...
... Wis. - The Madison-based National Stem Cell Ban...tem cells from the University of California-San F...available on the federal registry. , ,Beth Donley,...ute , which houses the stem cell bank, said the or...ave all 21 federally approved lines. , ,"We,re ver...
...Wis. - The Center for Advanced Technology and In...ogy-based economic development programs. , ,An awa...uncil recognizes CATI,s work in developing a $40 ...uch as Kraft Foods , S.C. Johnson , and Boeing ...ments, five company product line expansions, and t...
... Wis. - Genetically engineered mice are very expe...ny has developed a method for producing similarly ...io Corp. , a privately-held biopharmaceutical firm...urdles associated with producing modified mice at ... animals instead. , ,Mirus has begun using its spe...
Other Biology Technology:Summer venture investments total $18 million for Wisconsin start ups 2Summer venture investments total $18 million for Wisconsin start ups 3Summer venture investments total $18 million for Wisconsin start ups 4Nation's only stem cell bank will receive UC-San Francisco cell line 2Mirus provides low-cost way to modify genes 2
(Date:12/2/2008)...ywhere else in the world. This is having a major i...nvironment and effect of cities on rural areas. On...ca,s history is being over-looked. , Joy Clancy ...blem in the current issue of the African Journal ...the African population was rural, today 38% live i...
(Date:12/2/2008)...tion due to climate change, pollution and human ac... providing satellite data of the region for the la...ion with ESA,s future missions will be key in impl...icy called ,The European Union and the Arctic Regi...n the region such as the opening up of long-sought...
(Date:12/1/2008)...spread consumption advisories and uncertainty amon...w researchers at North Carolina State University h...d regulators around the country predict which area... a breakthrough that should help officials addres...es for specific water bodies and fish species. , ...
(Date:12/1/2008)...old a colloquium to examine what lies ahead in evo...isms. Leading researchers and students will discus...tion and even evolution from the perspectives of e...ity informatics dealing with microbes, plants, and...he event will take place at the Arnold and Mabel B...
Breaking Biology News(10 mins):ESA satellites focusing on the Arctic 2New model predicts hot spots for mercury in fish 2American Council on Exercise Offers 10 Tips for Surviving the Holidays 2847 1American Council on Exercise Offers 10 Tips for Surviving the Holidays 2847 2IDM Pharma to Present at BIO InvestorForum in San Francisco 1045 1IDM Pharma to Present at BIO InvestorForum in San Francisco 1045 2IDM Pharma to Present at BIO InvestorForum in San Francisco 1045 3Environmental Tectonics Corporations BioMedical Division Announces New Contract 1042 1Environmental Tectonics Corporations BioMedical Division Announces New Contract 1042 2Environmental Tectonics Corporations BioMedical Division Announces New Contract 1042 3Clarient Names Michael J Pellini M D Chief Operating Officer 2845 1Clarient Names Michael J Pellini M D Chief Operating Officer 2845 2Clarient Names Michael J Pellini M D Chief Operating Officer 2845 3Clarient Names Michael J Pellini M D Chief Operating Officer 2845 4
...wly identified gene expression profile could help ...will respond to chemotherapy treatment. Described ...urnal of Clinical Oncology (JCO), the new findings...y gene profiling as a predictor of clinical outcom...clinicians with insights into the mechanisms of dr...
... preliminary results from a study in Botswana, Har...d that people with HIV-1 subtype C in resource-poo...py, can achieve comparable results to those in the...livery system and infrastructure help ensure this ...005 issue of the Journal of Acquired Immune Defici...
...am of researchers led by scientists at Memorial Sl... new class of drugs -- now in early stage clinical... the BRAF gene. BRAF is a protein that plays a cen...ls and is mutated in the majority of patients with..., breast, and lung cancers. The findings, availabl...
...rding to research reported this week in Current Bi...e epicenter of the 2004 Sumatra-Andaman earthquake...mited, particularly when compared to damage from c...0 days after the tsunami of December 26, 2004, a t...Wildlife Conservation Society-Indonesia Program, a...
Other Biology News:Gene expression profile helps predict chemotherapy response in ovarian cancer patients 2Gene expression profile helps predict chemotherapy response in ovarian cancer patients 3New Therapeutic Target Identified In Inherited Brain Tumor Disorder 2Mutations in the BRAF gene predict sensitivity to a novel class of cancer drugs 2
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis.
Request Info
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, glycerol solution.
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates.
Biology Products: